This HTML5 document contains 175 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n22http://linked.opendata.cz/resource/drugbank/drug/DB00175/identifier/chemspider/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/AHFS/
n24http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n30http://linked.opendata.cz/resource/drugbank/dosage/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00175/identifier/wikipedia/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00175/identifier/pharmgkb/
n27http://bio2rdf.org/drugbank:
n17http://linked.opendata.cz/resource/drugbank/drug/DB00175/identifier/kegg-compound/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00175/identifier/bindingdb/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00175/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n26http://www.rxlist.com/cgi/generic/
n20http://linked.opendata.cz/resource/drugbank/patent/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00175/identifier/pubchem-substance/
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00175/identifier/kegg-drug/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00175/identifier/drugbank/
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n23http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n28http://www.drugs.com/cdi/
n6http://linked.opendata.cz/resource/drugbank/property/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00175/identifier/national-drug-code-directory/
xsdhhttp://www.w3.org/2001/XMLSchema#
n31http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00175
rdf:type
n3:Drug
n3:description
Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered. It is a ring-opened dihydroxyacid with a 6’-hydroxyl group that does not require <i>in vivo</i> activation. Pravastatin is one of the lower potency statins; however, its increased hydrophilicity is thought to confer advantages such as minimal penetration through lipophilic membranes of peripheral cells, increased selectivity for hepatic tissues, and a reduction in side effects compared with lovastatin and simvastatin.
n3:dosage
n30:271B5149-363D-11E5-9242-09173F13E4C5 n30:271B514A-363D-11E5-9242-09173F13E4C5 n30:271B514B-363D-11E5-9242-09173F13E4C5 n30:271B514C-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# FDA label
n3:group
approved
n3:halfLife
77 hours
n3:indication
For the treatment of hypercholesterolemia and to reduce the risk of cardiovascular disease.
n3:manufacturer
n4:271B511F-363D-11E5-9242-09173F13E4C5 n4:271B511D-363D-11E5-9242-09173F13E4C5 n4:271B511E-363D-11E5-9242-09173F13E4C5 n4:271B511B-363D-11E5-9242-09173F13E4C5 n4:271B511C-363D-11E5-9242-09173F13E4C5 n4:271B5119-363D-11E5-9242-09173F13E4C5 n4:271B511A-363D-11E5-9242-09173F13E4C5 n4:271B5117-363D-11E5-9242-09173F13E4C5 n4:271B5118-363D-11E5-9242-09173F13E4C5 n4:271B5115-363D-11E5-9242-09173F13E4C5 n4:271B5116-363D-11E5-9242-09173F13E4C5 n4:271B5113-363D-11E5-9242-09173F13E4C5 n4:271B5114-363D-11E5-9242-09173F13E4C5 n4:271B5112-363D-11E5-9242-09173F13E4C5
owl:sameAs
n10:DB00175 n27:DB00175
dcterms:title
Pravastatin
adms:identifier
n12:46504851 n13:D00893 n14:Pravastatin n15:PA451089 n16:54687 n17:C01844 n18:0003-5154-05 n19:DB00175 n21:20688 n22:49398
n3:mechanismOfAction
Pravastatin is structurally similar to the HMG, a substituent of the endogenous substrate of HMG-CoA reductase. Unlike its parent compound, mevastatin, and statins such as lovastatin and simvastatin, pravastatin does not need to be activated <i>in vivo</i>. Its hydrolyzed lactone ring mimics the tetrahedral intermediate produced by the reductase allowing the agent to bind with a much greater affinity than its natural substrate. The bicyclic portion of pravastatin binds to the coenzyme A portion of the active site. Pravastatin sodium produces its lipid-lowering effect in two ways. First, as a consequence of its reversible inhibition of HMG-CoA reductase activity, it effects modest reductions in intracellular pools of cholesterol. This results in an increase in the number of LDL-receptors on cell surfaces and enhanced receptor-mediated catabolism and clearance of circulating LDL. Second, pravastatin inhibits LDL production by inhibiting hepatic synthesis of VLDL, the LDL precursor.
n3:packager
n4:271B50FD-363D-11E5-9242-09173F13E4C5 n4:271B50FE-363D-11E5-9242-09173F13E4C5 n4:271B50F3-363D-11E5-9242-09173F13E4C5 n4:271B50FC-363D-11E5-9242-09173F13E4C5 n4:271B5101-363D-11E5-9242-09173F13E4C5 n4:271B5102-363D-11E5-9242-09173F13E4C5 n4:271B50FF-363D-11E5-9242-09173F13E4C5 n4:271B5100-363D-11E5-9242-09173F13E4C5 n4:271B5105-363D-11E5-9242-09173F13E4C5 n4:271B5106-363D-11E5-9242-09173F13E4C5 n4:271B5103-363D-11E5-9242-09173F13E4C5 n4:271B5104-363D-11E5-9242-09173F13E4C5 n4:271B5109-363D-11E5-9242-09173F13E4C5 n4:271B510A-363D-11E5-9242-09173F13E4C5 n4:271B5107-363D-11E5-9242-09173F13E4C5 n4:271B5108-363D-11E5-9242-09173F13E4C5 n4:271B50F5-363D-11E5-9242-09173F13E4C5 n4:271B50F6-363D-11E5-9242-09173F13E4C5 n4:271B50F4-363D-11E5-9242-09173F13E4C5 n4:271B50F9-363D-11E5-9242-09173F13E4C5 n4:271B50FA-363D-11E5-9242-09173F13E4C5 n4:271B50F7-363D-11E5-9242-09173F13E4C5 n4:271B50F8-363D-11E5-9242-09173F13E4C5 n4:271B50FB-363D-11E5-9242-09173F13E4C5 n4:271B50E9-363D-11E5-9242-09173F13E4C5 n4:271B50EA-363D-11E5-9242-09173F13E4C5 n4:271B50E7-363D-11E5-9242-09173F13E4C5 n4:271B50E8-363D-11E5-9242-09173F13E4C5 n4:271B50ED-363D-11E5-9242-09173F13E4C5 n4:271B50EE-363D-11E5-9242-09173F13E4C5 n4:271B50EB-363D-11E5-9242-09173F13E4C5 n4:271B50EC-363D-11E5-9242-09173F13E4C5 n4:271B50F1-363D-11E5-9242-09173F13E4C5 n4:271B50F2-363D-11E5-9242-09173F13E4C5 n4:271B50EF-363D-11E5-9242-09173F13E4C5 n4:271B50F0-363D-11E5-9242-09173F13E4C5 n4:271B510D-363D-11E5-9242-09173F13E4C5 n4:271B510E-363D-11E5-9242-09173F13E4C5 n4:271B510B-363D-11E5-9242-09173F13E4C5 n4:271B510C-363D-11E5-9242-09173F13E4C5 n4:271B5111-363D-11E5-9242-09173F13E4C5 n4:271B510F-363D-11E5-9242-09173F13E4C5 n4:271B5110-363D-11E5-9242-09173F13E4C5
n3:patent
n20:5622985 n20:1323836
n3:routeOfElimination
Approximately 20% of a radiolabeled oral dose is excreted in urine and 70% in the feces. After intravenous administration, 47% of total body clearance was via renal excretion, while 53% was eliminated by non-renal routes.
n3:synonym
Pravastatin acid (+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid Pravastatine Pravastatinum Pravastatina
n3:toxicity
Side effects include diarrhea, nausea, constipation, gas abdominal pain, myopathy, myositis, rhabdomyolysis, and hepatotoxicity. LD<sub>50</sub>= 12,000 mg/kg (orally in rat)
n7:hasAHFSCode
n8:24-06-08
n3:foodInteraction
Take without regard to meals. Avoid alcohol. Avoid drastic changes in dietary habit.
n3:proteinBinding
50% bound to human plasma proteins.
n3:salt
n3:synthesisReference
Kae Jong Chung, Joo Kyung Lee, Joo Woong Park, Dong Jin Seo, Sang Choon Lee, "Method for producing pravastatin precursor, ML-236B." U.S. Patent US6204032, issued October, 1976.
n23:hasConcept
n24:M0025879
foaf:page
n26:pravast.htm n28:pravastatin.html
n3:IUPAC-Name
n6:271B5151-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B5157-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B5156-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B5153-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B5154-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B5155-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B5167-363D-11E5-9242-09173F13E4C5 n6:271B514F-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B5169-363D-11E5-9242-09173F13E4C5 n6:271B5150-363D-11E5-9242-09173F13E4C5 n6:271B514D-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B514E-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n31:C10AA03
n3:H-Bond-Acceptor-Count
n6:271B515D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B515E-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B5158-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B5159-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B515B-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B515A-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B515C-363D-11E5-9242-09173F13E4C5
n3:absorption
Pravastatin is rapidly absorbed with peak plasma levels of the parent compound achieved 1 to 1.5 hours after administration. The average oral absorption of pravastatin is 34% and absolute bioavailability is 17%. These values however, are variable. Food decreases the systemic bioavailability but the lipid-lowering effect is not impacted. When 20 mg of pravastatin is given orally, the pharmacokinetic parameters are as follows: Cmax = 23.3-26.3 ng/mL; AUC = 54.7 to 62.2 ng•hr/mL.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
81093-37-0
n3:category
n3:containedIn
n5:271B5121-363D-11E5-9242-09173F13E4C5 n5:271B5122-363D-11E5-9242-09173F13E4C5 n5:271B5120-363D-11E5-9242-09173F13E4C5 n5:271B5135-363D-11E5-9242-09173F13E4C5 n5:271B5136-363D-11E5-9242-09173F13E4C5 n5:271B5133-363D-11E5-9242-09173F13E4C5 n5:271B5134-363D-11E5-9242-09173F13E4C5 n5:271B5139-363D-11E5-9242-09173F13E4C5 n5:271B513A-363D-11E5-9242-09173F13E4C5 n5:271B5137-363D-11E5-9242-09173F13E4C5 n5:271B5138-363D-11E5-9242-09173F13E4C5 n5:271B513D-363D-11E5-9242-09173F13E4C5 n5:271B513E-363D-11E5-9242-09173F13E4C5 n5:271B513B-363D-11E5-9242-09173F13E4C5 n5:271B513C-363D-11E5-9242-09173F13E4C5 n5:271B5141-363D-11E5-9242-09173F13E4C5 n5:271B5142-363D-11E5-9242-09173F13E4C5 n5:271B513F-363D-11E5-9242-09173F13E4C5 n5:271B5140-363D-11E5-9242-09173F13E4C5 n5:271B5125-363D-11E5-9242-09173F13E4C5 n5:271B5126-363D-11E5-9242-09173F13E4C5 n5:271B5123-363D-11E5-9242-09173F13E4C5 n5:271B5124-363D-11E5-9242-09173F13E4C5 n5:271B5129-363D-11E5-9242-09173F13E4C5 n5:271B512A-363D-11E5-9242-09173F13E4C5 n5:271B5127-363D-11E5-9242-09173F13E4C5 n5:271B5128-363D-11E5-9242-09173F13E4C5 n5:271B512D-363D-11E5-9242-09173F13E4C5 n5:271B512E-363D-11E5-9242-09173F13E4C5 n5:271B512B-363D-11E5-9242-09173F13E4C5 n5:271B512C-363D-11E5-9242-09173F13E4C5 n5:271B5131-363D-11E5-9242-09173F13E4C5 n5:271B5132-363D-11E5-9242-09173F13E4C5 n5:271B512F-363D-11E5-9242-09173F13E4C5 n5:271B5130-363D-11E5-9242-09173F13E4C5 n5:271B5145-363D-11E5-9242-09173F13E4C5 n5:271B5146-363D-11E5-9242-09173F13E4C5 n5:271B5143-363D-11E5-9242-09173F13E4C5 n5:271B5144-363D-11E5-9242-09173F13E4C5 n5:271B5147-363D-11E5-9242-09173F13E4C5 n5:271B5148-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B5163-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B5165-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B5166-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B5168-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B5162-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B5161-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B5164-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B5152-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n6:271B515F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B5160-363D-11E5-9242-09173F13E4C5